PR Newswire
MENLO PARK, Calif., March 9, 2017
MENLO PARK, Calif., March 9, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that its updated corporate presentation will be webcast from the 29th Annual ROTH Conference in Dana Point, Calif.
BioPharmX co-founder and President Anja Krammer will provide an updated overview of the company at the conference on Monday, March 13, at 10 a.m. PST in Pink – Salon 5 conference room of the Ritz Carlton Hotel.
The live webcast will be available at http://wsw.com/webcast/roth31/bpmx and a replay will be accessible for 90 days following the presentation.
The annual ROTH Conference, hosted by ROTH Capital Partners March 12 to 15, is one of the largest gatherings of institutional investors, private equity investors, VCs, company executives and service providers in the small- and mid-cap space.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biopharmx-to-present-at-29th-annual-roth-conference-300420872.html
SOURCE BioPharmX Corporation
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.